BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 2890913)

  • 1. Clinical use of the quinolones.
    Neu HC
    Lancet; 1987 Dec; 2(8571):1319-22. PubMed ID: 2890913
    [No Abstract]   [Full Text] [Related]  

  • 2. Quinolones in the treatment of serious infections.
    Webster A; Gaya H
    Rev Infect Dis; 1988; 10 Suppl 1():S225-33. PubMed ID: 3279496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical uses of nalidixic acid analogues: the fluoroquinolones.
    Høiby N
    Eur J Clin Microbiol; 1986 Apr; 5(2):138-40. PubMed ID: 3013628
    [No Abstract]   [Full Text] [Related]  

  • 4. Quinolones in the treatment of bronchopulmonary infections.
    Thys JP
    Rev Infect Dis; 1988; 10 Suppl 1():S212-7. PubMed ID: 3279495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity, pharmacokinetics, clinical safety and therapeutic efficacy of enoxacin in the treatment of patients with complicated urinary tract infections.
    Naber KG; Sörgel F; Gutzler F; Bartosik-Wich B
    Infection; 1985; 13(5):219-24. PubMed ID: 2933340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.
    Hooper DC; Wolfson JS
    Antimicrob Agents Chemother; 1985 Nov; 28(5):716-21. PubMed ID: 2936302
    [No Abstract]   [Full Text] [Related]  

  • 7. Quinolone antimicrobial agents in acute exacerbations of chronic bronchitis.
    Maesen FP; Davies BI; Teengs JP; Baur C
    Eur J Respir Dis Suppl; 1986; 146():585-90. PubMed ID: 3465584
    [No Abstract]   [Full Text] [Related]  

  • 8. Quinolones.
    Shah PM
    Prog Drug Res; 1987; 31():243-56. PubMed ID: 3326031
    [No Abstract]   [Full Text] [Related]  

  • 9. [Fluoroquinolones].
    Baykal M; Akalin E
    Mikrobiyol Bul; 1987 Apr; 21(2):151-7. PubMed ID: 3482120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.
    Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL
    Drugs; 1987; 34 Suppl 1():159-69. PubMed ID: 3481317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
    Wise R; Griggs D; Andrews JM
    Rev Infect Dis; 1988; 10 Suppl 1():S83-9. PubMed ID: 3162327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin.
    Van der Auwera P
    Infection; 1986; 14(3):142-4. PubMed ID: 2942489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of quinolones in respiratory tract infections.
    Maesen FP; Davies BI; Geraedts WH; Baur C
    Drugs; 1987; 34 Suppl 1():74-9. PubMed ID: 3325259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparative pharmacokinetics of five quinolones.
    Wise R; Lister D; McNulty CA; Griggs D; Andrews JM
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():71-81. PubMed ID: 3468102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro activity of new quinolones against Mycoplasma pathogenic to humans].
    Renaudin H; Quentin C; de Barbeyrac B; Bebear C
    Pathol Biol (Paris); 1988 May; 36(5):496-9. PubMed ID: 3136430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New oral quinolone compounds in chronic bronchitis].
    Davies BI; Maesen FP; Teengs JP; Baur C
    Infection; 1986; 14 Suppl 1():S73-8. PubMed ID: 2937739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacokinetics of new quinolones.
    Lode H; Höffken G; Prinzing C; Glatzel P; Wiley R; Olschewski P; Sievers B; Reimnitz D; Borner K; Koeppe P
    Drugs; 1987; 34 Suppl 1():21-5. PubMed ID: 3481323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of the 4-quinolones.
    Eggleston M; Park SY
    Infect Control; 1987 Mar; 8(3):119-25. PubMed ID: 3553053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic contribution of the new quinolones].
    Wolff M
    Rev Prat; 1987 Apr; 37(21):1209-14. PubMed ID: 3474759
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative in vitro activities of ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin against Bacteroides fragilis and Clostridium difficile.
    Edlund C; Nord CE
    Scand J Infect Dis; 1986; 18(2):149-51. PubMed ID: 2939556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.